Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097331
Status:
COMPLETED
Last Update Posted:
2015-04-13
First Post:
2004-11-22
Brief Title:
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomised Double-blind Placebo-controlled Parallel Group Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 150 - 1200mg Twice Daily in Subjects With Relapsing Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis MS using data from magnetic resonance imaging MRI scans as the main measure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None